 |
|
|
|
|
| |
|
|
| |
●
Founders
●
Scientific Advisory Board
●
Management |
Constellation Pharmaceutical Founders
Constellation
Pharmaceuticals Founders: Unmatched insight into the
biology of Epigenetics
Constellation’s founders are pioneers, authorities and
core thought leaders within the field of Epigenetics,
having made innumerable advances in our understanding of
the intricate biology of the epigenome and histone
modification.
Together, our founders represent an unparalleled
knowledge base of biological insight into this newly
developing and highly exciting field of biology.
Danny Reinberg, Ph.D.
Professor of Biochemistry at the New York University
School of Medicine
Howard Hughes Medical Institute Investigator
Dr. Reinberg is a world-recognized leader in the fields
of mammalian transcriptional regulation, chromatin
dynamics and epigenetic regulation. His numerous
advances are detailed in over 180 publications. Key
contributions include:
-
Identifying the structural and functional
characterization of key components of the human gene
expression machinery;
-
Discovering several chromatin remodeling factors and
key insights into the mechanisms by which genes are
activated and expressed in the context of chromatin;
and,
-
Purifying and characterizing of several histone
methyltransferases and chromatin modifying complexes
that have shed great insight into the regulatory
interplay between histone modification and gene
expression.
Yang Shi, Ph.D
Professor of Pathology at
Harvard Medical School
Dr. Shi is a noted leader in the field of histone
demethylases, having discovered and characterized the
first member of this class of enzymes, and has made key
contributions to our understanding of mechanism and
implications of epigenetic modification, gene regulation
and genetic disease. Notable achievements include:
-
Discovering and
characterizing LSD1, the first histone demethylase;
-
Identifying and and characterizing of several JmjC
containing histone demethylases;
-
Elucidating the role
of deficiencies in specific histone demethylation
activity and X-linked mental retardation; and,
-
Establishing critical
biochemical and structural insights into the
chromatin specificity of histone demethylases.
David Allis, Ph.D
Head of the Laboratory of
Chromatin Biology at Rockefeller University
Member of the National Academy of Sciences
A leader in the field of chromatin biology, Dr. Allis
has pioneered experimental and theoretical studies
elucidating the mechanisms by which post-translational
modifications of histones regulate the functions of
chromatin and opened a new era in chromatin biology and
our understanding of genome function. Key contributions
include:
-
Demonstrating the
identity between biochemically purified histone
modifying enzymes and genetically defined
transcription co-activators;
-
Establishing a
critical link between covalent histone modifications
and gene activation; and,
-
Refining the current
paradigm referred to as the ‘histone code
hypothesis’ to explain how cell signaling cascades
result in individual or combinatorial histone
modifications, forming an epigenetic code that
dictates specific functional outcomes through
downstream interactions with distinct combinations
of transcriptional regulatory factors.
Further
illustrating the knowledge represented within
Constellation Pharmaceuticals, please refer to
“Epigenetics,”
a book considered the pre-eminent work in the field,
written by two of our founders and one of our SAB
members.
Epigenetics
by C. David Allis, Thomas Jenuwein, Danny Reinberg, and
Marie-Laure Caparros.
Cold Spring Harbor Press. 2007.
|
|
|
|
|
|
